Human Genome Epidemiology Literature Finder
|
Records 1 - 10 (of 10 Records) |
| Query Trace: Prostatic Hyperplasia and CYP3A4[original query] |
|---|
| CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology reports 0 9 (3): 653-5. Tayeb Mohammed T, Clark Caroline, Sharp Linda, Haites Neva E, Rooney Patrick H, Murray Graeme I, Payne Simon N L, McLeod Howard |
| CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. British journal of cancer 2003 Mar 88 (6): 928-32. Tayeb M T, Clark C, Haites N E, Sharp L, Murray G I, McLeod H |
| CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. American journal of epidemiology 2004 Nov 160 (9): 825-41. Keshava Channa, McCanlies Erin C, Weston Ainsl |
| Joint effects of inflammation and androgen metabolism on prostate cancer severity. International journal of cancer. Journal international du cancer 2008 Sep 123 (6): 1385-9. Rebbeck Timothy R, Rennert Hanna, Walker Amy H, Panossian Saarene, Tran Teo, Walker Kyle, Spangler Elaine, Patacsil-Coomes Margerie, Sachdeva Rajeev, Wein Alan J, Malkowicz S Bruce, Zeigler-Johnson Charni |
| Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample. World journal of urology 2011 Apr 29 (2): 143-8. Berges Richard, Gsur Andrea, Feik Elisabeth, Höfner Klaus, Senge Theodor, Pientka Ludger, Baierl Andreas, Michel Martin C, Ponholzer Anton, Madersbacher Steph |
| The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug metabolism and pharmacokinetics 2012 Dec . Wang Z, Xiang Q, Cui Y, Zhao X, Zhou Y |
| Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the ?-adrenergic receptor antagonist. The aging male : the official journal of the International Society for the Study of the Aging Male 2017 Aug 1-7. Qian Xiaoqiang, Xu Ding, Liu Hailong, Lin Xiaoling, Yu Yongjiang, Kang Jian, Sheng Xujun, Xu Jianfeng, Zheng Siqun, Xu Danfeng, Qi J |
| Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Archives of pharmacal research 2021 11 44 (11): 1037-1049. Cho Chang-Keun, Kang Pureum, Park Hye-Jung, Lee Yun Jeong, Bae Jung-Woo, Jang Choon-Gon, Lee Seok-Yo |
| Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Frontiers in pharmacology 2021 10 12 718281. Villapalos-García Gonzalo, Zubiaur Pablo, Navares-Gómez Marcos, Saiz-Rodríguez Miriam, Mejía-Abril Gina, Martín-Vílchez Samuel, Román Manuel, Ochoa Dolores, Abad-Santos Francis |
| [Study of allelic variants of the CYP2D6 and CYP3A genes on the effectiveness and safety of tamsulosin therapy in patients with BPH: results of a pilot study]. Urologiia (Moscow, Russia : 1999) 2023 12 (6): 5-13. P Abdullaev Sh, N Shatokhin M, N Tuchkova S, P Abdullaev Sh, V Teodorovich O, B Loran O, A Sychev |
- Page last reviewed:Feb 1, 2024
- Content source: